What are your top takeaways from SGO 2024?

SGO 2024 was a great meeting with many excellent presentations. We are truly “moving the needle together”. The following presentations are each practice changing.

1. Duska et al., PMID 38521086: Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: randomized, double-bli...

SGO 2024 had a lot of updates of previously presented clinical trials - many of them from the ESMO conference from last year. So there were not many earth-shattering findings there.

A) A few important updates of previous studies:

RUBY study - looking at the addition of dostarlimab IO to chemo for adva...